Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 527

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Totally Drug-Resistant Tuberculosis in India

Udwadia, Z. F., Amale, R. A., Ajbani, K. K., Rodrigues, C.·2012·Clinical Infectious Diseases

Abstract

TO THE EDITOR—Three years after extensively drug-resistant (XDR) tuberculosis was first described in 2006, Velayati et al [1] drew attention to the emergence of totally drug-resistant (TDR) tuberculosis in a cohort of 15 patients from Iran, resistant to all first- and second-line drugs. Since the first cases of XDR tuberculosis in India were reported from the P. D. Hinduja National Hospital and Medical Research Centre [2], physicians here have grappled with increasingly resistant strains of tuberculosis. We describe the first patients from India with TDR tuberculosis. Drug susceptibility testing (DST) was performed at the Hinduja Hospital, the city's busiest referral laboratory and a Revised National Tuberculosis Control Programme (RNTCP) accredited laboratory for Mumbai. Each of the 4 patients was resistant to all first-line (isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin) and second-line (ofloxacin, moxifloxacin, kanamycin, amikacin, capreomycin, para-aminosalicylic acid, and ethionamide) drugs tested. All DSTs were performed by Mycobacterial Growth Indicator Tube 960 at critical concentrations for first-line and second-line drugs recommended by the World Health Organization (WHO). In addition, 3 of the patients underwent genotypic DST analysis using the MTBDRplus and MTBDRsl line probe assays (Hain Life Science). A careful audit of their prescriptions revealed that these 3 patients had received erratic, unsupervised second-line drugs, added individually and often in incorrect doses, from multiple private practitioners (mean, 4 physicians during a 18-month period) in an attempt to cure their multidrug-resistant (MDR) tuberculosis (Table 1). The latest WHO global resistance report estimated 110 132 cases of MDR tuberculosis from India in 2006, which accounts for 20% of the world’s MDR tuberculosis load [3]. Although India's RNTCP has been a tremendous success, patients with MDR tuberculosis currently are not covered, with only 1% having access to Directly Observed Treatment, Short-course (DOTS)–Plus initiatives [4]. The vast majority of these unfortunate patients seek care from private physicians in a desperate attempt to find a cure for their tuberculosis. This sector of private-sector physicians in India is among the largest in the world and these physicians are unregulated both in terms of prescribing practice and qualifications. A study that we conducted in Mumbai showed that only 5 of 106 private practitioners practicing in a crowded area called Dharavi could prescribe a correct prescription for a hypothetical patient with MDR tuberculosis [5]. The majority of prescriptions were inappropriate and would only have served to further amplify resistance, converting MDR tuberculosis to XDR tuberculosis and TDR tuberculosis. We would urge that patients with MDR tuberculosis only be treated within the confines of government-sanctioned DOTS-Plus programs to prevent the emergence and spread of this untreatable form of tuberculosis. Treatment and Resistance Details in 4 Patients Treated With First- and Second-Line Drugs for Tuberculosis Abbreviations: gyrA, gyrase subunit A; inhA, enoyl subunit A; katG, catalase peroxidise gene; rpoβ, RNA polymerase β subunit; rrs,16S ribosomal RNA. The first- and second-line drugs to which susceptibility was checked included isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, moxifloxacin, ofloxacin, para-aminosalisylate, and ethionamide. Treatment and Resistance Details in 4 Patients Treated With First- and Second-Line Drugs for Tuberculosis Abbreviations: gyrA, gyrase subunit A; inhA, enoyl subunit A; katG, catalase peroxidise gene; rpoβ, RNA polymerase β subunit; rrs,16S ribosomal RNA. The first- and second-line drugs to which susceptibility was checked included isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, moxifloxacin, ofloxacin, para-aminosalisylate, and ethionamide. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/cir889

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 527

Metadata

Authors
Udwadia, Z. F., Amale, R. A., Ajbani, K. K., & Rodrigues, C.
Venue
Clinical Infectious Diseases
Published
2011-12-21
Volume
54
Issue
4
Pages
579-581
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2150389899
Cited by
527
References
1
FWCI
45.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Totally Drug-Resistant Tuberculosis in India. https://app.cochat.ai/papers/10.1093/cid/cir889
The paper
Udwadia, Z. F., Amale, R. A., Ajbani, K. K., & Rodrigues, C. (2012). Totally Drug-Resistant Tuberculosis in India. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cir889

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.